Stock Scorecard



Stock Summary for Astria Therapeutics Inc (ATXS) - $9.73 as of 11/20/2024 7:47:06 PM EST

Total Score

10 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ATXS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ATXS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ATXS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ATXS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ATXS (28 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0

Latest News for for ATXS

Global Allergy Diagnostics and Therapeutics Market Size/Share Worth USD 78,036.1 Million by 2033 at a 8.1% CAGR: Custom Market Insights ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value ) 11/18/2024 5:30:00 PM
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer 9/16/2024 11:00:00 AM
Is Artivion ( AORT ) Stock Outpacing Its Medical Peers This Year? 3/12/2024 1:40:00 PM
Glenmark Pharma reports net loss of Rs 331 cr in Q3 FY24 | Capital Market News 2/15/2024 5:46:00 AM
Glenmark Pharma Q3 results: Standalone loss at Rs 20 cr, revenue dips 38.4% | Company Results 2/14/2024 5:55:00 PM
Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24 2/14/2024 3:01:00 PM
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying - Astria Therapeutics ( NASDAQ:ATXS ) , InnSuites Hospitality ( AMEX:IHT ) 12/26/2023 11:49:00 AM
As we move up the value chain, developing comprehensive portfolio for global market to be key priority: Glenn Saldanha, CMD, Glenmark Pharmaceuticals 12/21/2023 7:10:00 AM
Is a Surprise Coming for Astria Therapeutics ( ATXS ) This Earnings Season? 11/10/2023 2:10:00 PM
Suncor ( SU ) Q3 Earnings Preview: What Investors Need to Know 11/7/2023 12:50:00 PM

Financial Details for ATXS

Company Overview

Ticker ATXS
Company Name Astria Therapeutics Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 9.73
Price 4 Years Ago 12.84
Last Day Price Updated 11/20/2024 7:47:06 PM EST
Last Day Volume 545,049
Average Daily Volume 218,041
52-Week High 16.90
52-Week Low 4.43
Last Price to 52 Week Low 119.64%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -3.53
Free Cash Flow Ratio 1.60
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 22.38
Total Cash Per Share 6.10
Book Value Per Share Most Recent Quarter 4.26
Price to Book Ratio 2.10
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 56,434,000
Market Capitalization 549,102,820
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -40.62%
Reported EPS 12 Trailing Months -2.18
Reported EPS Past Year -1.23
Reported EPS Prior Year -2.42
Net Income Twelve Trailing Months -100,044,000
Net Income Past Year -72,891,000
Net Income Prior Year -51,834,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 344,300,000
Total Cash Past Year 246,500,000
Total Cash Prior Year 226,400,000
Net Cash Position Most Recent Quarter 344,300,000
Net Cash Position Past Year 246,500,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 243,116,000
Total Stockholder Equity Prior Year 221,216,000
Total Stockholder Equity Most Recent Quarter 341,654,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -94,429,000
Free Cash Flow Per Share Twelve Trailing Months -1.67
Free Cash Flow Past Year -68,470,000
Free Cash Flow Prior Year -43,624,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.23
MACD Signal 0.00
20-Day Bollinger Lower Band 9.36
20-Day Bollinger Middle Band 11.22
20-Day Bollinger Upper Band 13.08
Beta 0.71
RSI 32.11
50-Day SMA 10.78
150-Day SMA 9.22
200-Day SMA 9.83

System

Modified 11/20/2024 6:26:47 PM EST